← Back to patent-cliff list
司美格鲁肽
Tier A — Act nowSemaglutide · all drugs expiring in 2031 →
诺和诺德（Novo Nordisk）
Originator
2017
First approval
2031
Expiry (public)
$18.4B *
Peak sales
化学药
Type
Targets：GLP1R
Brand：Ozempic、Rybelsus、Wegovy
Indications (approved)：超重、肥胖症、二型糖尿病、心脏和血管疾病
Regional status
US
批准上市
2017-12-05
EU
批准上市
2018-02-08
China
批准上市
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Also available in our peptide catalogue
Frequently asked questions
What are the approved indications of Semaglutide?
Approved indications include: 超重, 肥胖症, 二型糖尿病, 心脏和血管疾病.
When does the Semaglutide patent expire?
Based on public sources, the Semaglutide patent expires in 2031.
How do I get a quote for Semaglutide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24